SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (2497)9/16/2010 11:04:49 AM
From: Biomaven  Read Replies (1) | Respond to of 3027
 
The real question is how much you trust the public statements of the TEVA's CEO:

We are confident that we are very close to getting the approval for our generic version of deep vein thrombosis treatment Lovenox after providing all the answers requested by the FDA.

If you take his statement at face value, it's hard to argue that MNTA is underpriced here. My gut tells me that its unlikely that Teva came up with the miracle sauce prior to the FDA's 5-part test, and so they will have to rework their application. That belief of mine implies he's just talking his book here, but who knows.

Peter



To: tom pope who wrote (2497)9/16/2010 12:02:27 PM
From: Jeffry K. Smith1 Recommendation  Read Replies (1) | Respond to of 3027
 
"I'm getting the feeling that people here and on iHub are reading a different set of facts from those available to other market participants."

What makes you say that? I haven't gotten the impression that the information on IH is unavailable (I've seen plenty of sources cited), just that it may not be understandable! :-(


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News